Literature DB >> 26563335

[Diagnosis and treatment of sarcoidosis. Current standards].

B C Frye1, J C Schupp1, T L Köhler1, J Müller-Quernheim2.   

Abstract

Sarcoidosis is a granulomatous disease that mainly affects the lungs and intrathoracic lymph nodes; however, virtually any organ can be affected. As an orphan disease, recommendations are mainly based on observational or small randomized studies as well as experts' opinion. Diagnosing sarcoidosis requires proof of non-necrotizing granulomas in patients with a compatible symptomatic pattern and the exclusion of other granulomatous diseases. Granulomas can be detected best in the lungs or intrathoracic lymph nodes. Therefore, bronchoscopy and endobronchial ultrasound with biopsies of lymph nodes are the major tools to diagnose sarcoidosis. Frequently, close follow-up and symptomatic therapy are sufficient to allow for spontaneous resolution. In case of functional organ impairment, cardial or CNS involvement, or other complications, steroid therapy is necessary with a starting dose of 0.5 mg/kg body weight that should be tapered-off over 6-12 months. Steroid-refractory disease can be treated by adding methotrexate or azathioprine, two drugs long known in sarcoidosis treatment. Monoclonal antibodies against TNF and lung transplantation are further therapeutic options.

Entities:  

Keywords:  Bronchoscopy; Granuloma, non-necrotizing; Granulomatous disease; Lung diseases, interstitial; Steroids

Mesh:

Substances:

Year:  2015        PMID: 26563335     DOI: 10.1007/s00108-015-3757-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis.

Authors:  M W Ziegenhagen; M E Rothe; M Schlaak; J Müller-Quernheim
Journal:  Eur Respir J       Date:  2003-03       Impact factor: 16.671

Review 2.  Complication rate of endosonography (endobronchial and endoscopic ultrasound): a systematic review.

Authors:  M B von Bartheld; A van Breda; J T Annema
Journal:  Respiration       Date:  2014-01-16       Impact factor: 3.580

Review 3.  Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.

Authors:  Shanthi Paramothayan; Paul W Jones
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

Review 4.  Diagnosis of Sarcoidosis.

Authors:  Thomas E Wessendorf; Francesco Bonella; Ulrich Costabel
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 5.  Sarcoidosis.

Authors:  Dominique Valeyre; Antje Prasse; Hilario Nunes; Yurdagul Uzunhan; Pierre-Yves Brillet; Joachim Müller-Quernheim
Journal:  Lancet       Date:  2013-10-01       Impact factor: 79.321

6.  Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.

Authors:  Adriane D M Vorselaars; Anouk Verwoerd; Coline H M van Moorsel; Ruth G M Keijsers; Ger T Rijkers; Jan C Grutters
Journal:  Eur Respir J       Date:  2013-08-29       Impact factor: 16.671

7.  Outcome of the treatment for sarcoidosis.

Authors:  G W Hunninghake; S Gilbert; R Pueringer; C Dayton; C Floerchinger; R Helmers; R Merchant; J Wilson; J Galvin; D Schwartz
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405

8.  18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.

Authors:  Ruth G Keijsers; Fred J Verzijlbergen; Wim J Oyen; Jules M van den Bosch; Henk J Ruven; Heleen van Velzen-Blad; Jan C Grutters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

9.  Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.

Authors:  M A Judson; R P Baughman; U Costabel; S Flavin; K H Lo; M S Kavuru; M Drent
Journal:  Eur Respir J       Date:  2008-02-06       Impact factor: 16.671

Review 10.  Neurological complications of sarcoidosis.

Authors:  Barney J Stern
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710

View more
  1 in total

Review 1.  [Sarcoidosis].

Authors:  B C Frye; J C Schupp; T C Köhler; R E Voll; J Müller-Quernheim
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.